Sanofi (SNY) Tops Q2 EPS by 84c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
July 26, 2024 7:33 AM EDTArgus analyst Jasper Hellweg raised the price target on Sanofi-Aventis (NASDAQ: SNY) to $60.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "Our rating on Sanofi SA (NGS: SNY), a leading global pharmaceutical company, is BUY. We like Sanofis diverse range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products. The... More
